Systems Biomedical Key Laboratory of JiangXi Province; Jiujiang, PR China; Hangzhou Yishan Biotechnology Co., Ltd; Zhejiang Proveince, Hangzhou, PR China.
Prion. 2013 Jul-Aug;7(4):335-40. doi: 10.4161/pri.26020. Epub 2013 Aug 7.
The objective of the present study was to systematically explore the effects of 32K Da protein (32KP) on postmenopausal osteoporosis. Eighty 3-mo-old female Sprague-Dawley rats were employed and randomly divided into one sham-operated group (SHAM) and five ovariectomy (OVX) subgroups as OVX (control), OVX with 17-ethinylestradiol (E2, 25 g/kg/day), OVX with 32KP of graded doses (50, 50, or 150 mg/kg/day). 32KP or E2 diet was fed on week 4 after operation, for 16 weeks. Bone mass, bone turnover and strength were evaluated by dual-energy X-ray absorptiometry (DEXA), biochemical markers and three-point bending test, respectively. Femur marrow cavity was observed by light microscopy via hematoxylin-eosin staining. It is observed that different dosage treatment of 32KP increased the body weight and prevented the loss of bone mass induced by OVX. The prevention effect against bone loss was presumably due to the altering of the rate of bone remodeling. The bone mineral density and bone calcium content in OVX rats were lower than that in the control group, suggesting that 32KP was able to prevent significant bone loss. In addition, the data from three point bending test and femur sections showed that 32KP treatment enhanced bone strength and reduced the marrow cavity of the femur in OVX rats. In the serum and urine assay, 32KP decreased urinary deoxypyridinoline and calcium concentrations; however, serum alkaline phosphatase activities were not inhibited. It suggested that amelioration of bone loss was changed via inhibition of bone reabsorption. Our findings indicated that 32KP might be a potential alternative drug for the prevention and treatment of postmenopausal osteoporosis.
本研究旨在系统探讨 32KDa 蛋白（32KP）对绝经后骨质疏松症的影响。采用 80 只 3 月龄雌性 Sprague-Dawley 大鼠，随机分为假手术组（SHAM）和 5 个去卵巢组（OVX），即 OVX（对照组）、OVX 加 17β-雌二醇（E2，25μg/kg/天）、32KP 不同剂量（50、50 或 150mg/kg/天）组。术后第 4 周开始给予 32KP 或 E2 饮食，共 16 周。采用双能 X 线吸收法（DEXA）、生化标志物和三点弯曲试验分别评估骨量、骨转换和强度，通过苏木精-伊红染色观察股骨骨髓腔的光镜变化。结果发现，不同剂量的 32KP 处理增加了体重，预防了 OVX 引起的骨量丢失。这种防止骨丢失的作用可能是由于改变了骨重塑的速度。与对照组相比，OVX 大鼠的骨密度和骨钙含量较低，表明 32KP 能够预防明显的骨丢失。此外，三点弯曲试验和股骨切片的数据表明，32KP 处理增强了 OVX 大鼠的骨强度并减少了股骨骨髓腔。在血清和尿液检测中，32KP 降低了尿脱氧吡啶啉和钙浓度；然而，血清碱性磷酸酶活性未受抑制。这表明通过抑制骨吸收来改善骨丢失。我们的研究结果表明，32KP 可能是一种治疗绝经后骨质疏松症的潜在替代药物。
